

Tirzepatide (Mounjaro) implementation update 14 August 25

Thank you for your support in working with us to implement the NHS England requirements for Tirzepatide prescribing for weight management in Primary Care. All elements are now in place, here is an update:

Primary Care Delivery Model and offer to Practices – many thanks for responding to the Expressions of Interest (EOI) offer of a LES for the delivery of Tirzepatide and the quick turnaround of responses.

90% of Practices have signed up to the LES and this covers 91% of the potentially eligible patients in cohort 1. We advise that once training and systems are in place that **Practices may start to prescribe tirzepatide and refer to the BSOP wraparound care programme.**

Charlotte Keele Medical Practice have kindly shared an example of a draft Practice Tirzepatide SOP that you may find useful – Please email bnssg.medicines-optimisation@nhs.net if you would like a copy.

We would be grateful to those Practices signed up to the LES if you could provide us with a Practice lead so that we have a point of contact to support and work with us going forward – please complete this very quick form with Practice, lead name and contact details:

<https://forms.office.com/Pages/ResponsePage.aspx?id=sITDN7CF9Ueylge0jXdO4wwBWdmyl4pKjquML-WsCvIUQVVVOVTBCSE1KRTk3V0lxUUY0UTVXMFc5VC4u>

We are working with Practices to cover the small number of gaps we have within PCNs to make access as equitable as possible and will update you as soon as possible.

Prescribing guidance, training and other resources – the [Weight Management – Tirzepatide](#) page on Remedy collates all the information that has been provided to date and is the central repository for Tirzepatide prescribing information. Please do share with colleagues.

BSOP wraparound care – Living Well Taking Control who are providing the Behavioural Support for Obesity Prescribing (BSOP) programme have started to receive referrals from BNSSG Practices. Many thanks to those who have already referred to BSOP they have provided very positive feedback:

'Practices have used the correct referral form, including all necessary information, such as the declaration and patient eligibility confirmation. This has been greatly appreciated, as it has streamlined the process and minimised the need for follow-up queries, allowing us to contact patients promptly.'

Oviva – the Weight Management Working Group has been made aware that there have been some issues with contact and referrals to Oviva. Where issues are known the ICB acute contract team have been able to resolve. Please contact bnssg.acutecontracting@nhs.net if there are persistent problems.

Secondary care requests – we have been made aware that secondary care have asked a small number of patients to discuss tirzepatide eligibility with their GP where they may not meet the cohort 1 criteria. We are working with our colleagues in secondary care to ensure their clinical teams understand the scope within which GPs can make referral to specialist weight management services and prescribe tirzepatide.

Year 2 and beyond

The Weight Management Group are starting to look at how outcomes can be measured and work on options for the delivery model for year 2 and beyond. Practice feedback and experiences in addition to patient experiences and outcomes will help inform this work. The group is also looking at the wider weight management pathway and provider models to ensure equity of access and treatment across BNSSG.

We will update you with further information as soon as it becomes available to share with you.
bnssg.medicines-optimisation@nhs.net